TY  - RPRT
TI  - A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.
AU  - Suzanne Jones
AU  - Gerald Falchook
AU  - Stephanie Graff
AU  - Edward Arrowsmith
AU  - Deepak Kilari
AU  - Todd A Gersten
AU  - Maen Hussein
AU  - Ivor Percent
AU  - Howard A Burris
PY  - 2026
DO  - 10.1093/oncolo/oyag279
UR  - https://pubmed.ncbi.nlm.nih.gov/42485262/
ID  - 42485262
ER  -